AstraZeneca posts CAPItello-281 results in PTEN-deficient prostate cancer; registers AZD4954 Phase 1Sep 10Weekly roundup, 2 itemsAstraZenecaAZD4954
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studiesAug 21Weekly roundup, 7 itemsBioNTech SEPenbraya
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply dealAug 3Quarterly updateORIC Pharmaceuticals
New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapyJul 30Trial updateAmgenxaluritamig
ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPCJul 23Trial updateBayerdarolutamide
Kairos Pharma signs research agreement with Bayer to test ENV-105 with XOFIGO in prostate cancerJul 22Clinical readoutKairos Pharma, LTD.radium ra 223 dichloride
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
Telix and FDA align on ProstACT Global Phase 3 protocol, IND amendment pendingJul 2Clinical readoutTelix Pharmaceuticals Ltd
AstraZeneca posts Phase 3 LOGOS, KALOS asthma results; updates Soliris labelJul 2Weekly roundup, 5 itemsAstraZenecaAZD4045
Sign inSign in